Cargando…
Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases
AIM: In order to avoid the complications associated with thromboembolic disease, patients with this condition typically are placed on long-term anticoagulant therapy. This report compares bleeding complications in this patient population by level of achieved INR. MATERIALS AND METHODS: During the 6-...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC384377/ https://www.ncbi.nlm.nih.gov/pubmed/14975176 http://dx.doi.org/10.1186/1468-6708-5-1 |
_version_ | 1782121288694759424 |
---|---|
author | Yetkin, Ufuk Karabay, Özalp Önol, Hakan |
author_facet | Yetkin, Ufuk Karabay, Özalp Önol, Hakan |
author_sort | Yetkin, Ufuk |
collection | PubMed |
description | AIM: In order to avoid the complications associated with thromboembolic disease, patients with this condition typically are placed on long-term anticoagulant therapy. This report compares bleeding complications in this patient population by level of achieved INR. MATERIALS AND METHODS: During the 6-year period between January 1997 and January 2003, 386 patients with venous thromboembolism of the lower extremities were admitted to the Cardiovascular Surgery Outpatient Clinic of Alsancak State Hospital. Of the 386 patients, 198 (51.2%) were women, and the average age was 52.3 years. All diagnoses of venous thromboembolism were confirmed by means of Doppler ultrasonography. Further investigation showed occult neoplasms in 22 (5.6%) of the cases. We excluded the patients with occult disease, and the remaining 364 constituted our study population. RESULTS: Oral anticoagulation was standardized at 6 months' duration in all cases. We divided the patients into two groups. Group I consisted of 192 patients (52.7%) with INR values between 1.9 and 2.5; Group II comprised 172 patients with INR values between 2.6 and 3.5. Complications in each group were assessed and compared. The minor hemorrhage rate was 1.04% in Group I and 4.06% in Group II. The major hemorrhage rate was also 1.04% in Group I and was 6.3% in Group II. We determined that the complication rates for both minor and major hemorrhage were significant in patients with INR values above 2.5. CONCLUSION: Oral anticoagulation must be followed closely in patients with venous thromboembolism. Higher INR levels are associated with significant increases in hemorrhage and associated complications. INR values of 2.0 to 2.5 are sufficient for long-term anticoagulant therapy, ensuring ideal anticoagulation levels and minimizing the complication rate. |
format | Text |
id | pubmed-384377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-3843772004-04-06 Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases Yetkin, Ufuk Karabay, Özalp Önol, Hakan Curr Control Trials Cardiovasc Med Research AIM: In order to avoid the complications associated with thromboembolic disease, patients with this condition typically are placed on long-term anticoagulant therapy. This report compares bleeding complications in this patient population by level of achieved INR. MATERIALS AND METHODS: During the 6-year period between January 1997 and January 2003, 386 patients with venous thromboembolism of the lower extremities were admitted to the Cardiovascular Surgery Outpatient Clinic of Alsancak State Hospital. Of the 386 patients, 198 (51.2%) were women, and the average age was 52.3 years. All diagnoses of venous thromboembolism were confirmed by means of Doppler ultrasonography. Further investigation showed occult neoplasms in 22 (5.6%) of the cases. We excluded the patients with occult disease, and the remaining 364 constituted our study population. RESULTS: Oral anticoagulation was standardized at 6 months' duration in all cases. We divided the patients into two groups. Group I consisted of 192 patients (52.7%) with INR values between 1.9 and 2.5; Group II comprised 172 patients with INR values between 2.6 and 3.5. Complications in each group were assessed and compared. The minor hemorrhage rate was 1.04% in Group I and 4.06% in Group II. The major hemorrhage rate was also 1.04% in Group I and was 6.3% in Group II. We determined that the complication rates for both minor and major hemorrhage were significant in patients with INR values above 2.5. CONCLUSION: Oral anticoagulation must be followed closely in patients with venous thromboembolism. Higher INR levels are associated with significant increases in hemorrhage and associated complications. INR values of 2.0 to 2.5 are sufficient for long-term anticoagulant therapy, ensuring ideal anticoagulation levels and minimizing the complication rate. BioMed Central 2004 2004-02-18 /pmc/articles/PMC384377/ /pubmed/14975176 http://dx.doi.org/10.1186/1468-6708-5-1 Text en Copyright © 2004 Yetkin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Yetkin, Ufuk Karabay, Özalp Önol, Hakan Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title | Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title_full | Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title_fullStr | Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title_full_unstemmed | Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title_short | Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases |
title_sort | effects of oral anticoagulation with various inr levels in deep vein thrombosis cases |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC384377/ https://www.ncbi.nlm.nih.gov/pubmed/14975176 http://dx.doi.org/10.1186/1468-6708-5-1 |
work_keys_str_mv | AT yetkinufuk effectsoforalanticoagulationwithvariousinrlevelsindeepveinthrombosiscases AT karabayozalp effectsoforalanticoagulationwithvariousinrlevelsindeepveinthrombosiscases AT onolhakan effectsoforalanticoagulationwithvariousinrlevelsindeepveinthrombosiscases |